Tranexamic Acid and Spontaneous Chronic Urticaria (TACUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03789422|
Recruitment Status : Not yet recruiting
First Posted : December 28, 2018
Last Update Posted : May 6, 2019
Spontaneous chronic urticaria (UCS) is a disease that affects 1% of the general population with a potentially severe impact on quality of life. Most patients respond favorably to long-term antihistamine treatment, but sometimes it is necessary to give a high dose (4 times the formal dose, Berlin consensus 2016). These high doses are often accompanied by side effects requiring cessation of treatment. The therapeutic alternative is then omalizumab, an expensive biotherapy. UCS is secondary to non-specific mast cell activation. It has been shown to be associated with activation of fibrinolysis that correlates with the severity of symptoms. Patients with UCS resistant to levocetirizine were shown to have higher D-dimer levels than patients who responded to antihistamines. Tranexamic acid is a molecule with antifibrinolytic propertiesSeveral cases of severe chronic urticaria responding favorably to treatment with tranexamic acid have been reported. In our department, Investigators also noticed the improvement of some of their patients on tranexamic acid. The combination of these two treatments appears to be synergistic: action on histamine receptors and control of fibrinolysis.
The investigators propose to evaluate the association of tranexamic acid and levocetirizine for the treatment of chronic spontaneous urticaria.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Spontaneous Urticaria||Drug: association of levocetirizine and tranexamic acid Drug: Levocetirizine only||Phase 4|
Multicentric controlled randomized crossover study, double-blind To evaluate the efficacy and safety of levocetirizine 10mg / day + tranexamic acid (AT) 2g / day versus levocetirizine 20mg / day alone in the chronic treatment of chronic urticaria evaluated at 4 weeks.
A hierarchical analysis will be implemented in the following order:
- Non-inferiority of the combination levocetirizine 10 mg / day + tranexamic acid (TA) 2 g / day versus levocetirizine alone 20 mg / day in terms of effectiveness
- Superiority of the combination levocetirizine 10 mg / day + tranexamic acid (AT) 2 g / day versus levocetirizine alone 20 mg / day in terms of tolerance
- Superiority of levocetirizine 10mg / day + tranexamic acid (AT) 2g / day versus levocetirizine alone 20mg / day in terms of effectiveness Each objective will be tested sequentially if and only if the previous objective is validated.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Multicentric controlled randomized crossover study, double-blind|
|Masking:||Double (Participant, Investigator)|
|Masking Description:||Double blind|
|Official Title:||Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind|
|Estimated Study Start Date :||July 2019|
|Estimated Primary Completion Date :||January 2021|
|Estimated Study Completion Date :||January 2021|
Active Comparator: Association drugs
levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
Drug: association of levocetirizine and tranexamic acid
levocetirizine 10 mg/day + tranexamic acid 2 g/day
Active Comparator: one drug
Levocetirizine 20 mg/day for a month
Drug: Levocetirizine only
levocetirizine 20 mg/day
- Evolution of the Urticaria Activity Score 7 (UAS7) [ Time Frame: 28 days ]Evolution of the UAS7 score between the beginning (J0) and the end (J28) of the treatment period. To calculate the score, the patient rates the number of papules and itching intensity from 0 to 3 daily for 7 days. 0 corresponds to no papules and no itching, 3 corresponds to more than 50 papules per 24h and intense itching that can cause daily life. This makes a score of 0 to 6 per day accumulated over 7 days, ranging from 0 to 42.
- Tolerance of the association tranexamic acid and levocetirizine [ Time Frame: 28 days ]Number of adverse events
- To demonstrate the non-inferiority of levocetirizine 10mg / day + tranexamic acid (AT) 2g / day versus levocetirizine alone 20mg / day in terms of efficacy on the Angioedema Activity Score (AAS) [ Time Frame: 28 days ]Evolution of the AAS score between the beginning (J0) and the end (J28) of the end of treatment. The AAS score is a The AAS consists of 5 questions as well as an opening question. A score between 0 and 3 is assigned to every answer field. The question scores are summed up to an AAS day sum score, 7 AAS day sum scores to an AAS week sum score (AAS7). Accordingly, the minimum and maximum possible AAS scores are 0-15 (AAS day sum score), 0-105 (AAS7).
- Clinical characteristics of responders [ Time Frame: 28 days ]Identify the clinical characteristics of responders to the combination rather than antihistamines alone.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789422
|Contact: Raouf ZOUGLECH, MDS||4 76 76 78 38 ext firstname.lastname@example.org|
|Contact: Tiphaine Montagnon||4 76 76 68 14 ext email@example.com|
|CHU Grenoble-Alpes||Not yet recruiting|
|Grenoble, France, 38043|
|Contact: Raouf ZOUGLECH, MDS 4 76 76 78 38 ext 0033 firstname.lastname@example.org|
|Principal Investigator: Laurence BOUILLET, PhD|
|Principal Investigator:||Laurence BOUILLET, PhD||Internal Medicine - University Hospital Grenoble-Alpes|